CAS 1012886-75-7

Paroxetine Related Compound E (4-(4-Fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine hydrochloride)

CAS : 1012886-75-7

Compounds containing an unfused pyridine ring in the structure, nesoi

Formule : C₁₂H₁₄FN·HCl

Couleur et forme : White Powder

Masse moléculaire : 191.11103

Ref: 45-1500207

4-(4-Fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine hydrochloride (Paroxetine Hydrochloride Impurity)

CAS : 1012886-75-7

4-(4-Fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine hydrochloride (Paroxetine Hydrochloride Impurity)

Formule : C₁₂H₁₅ClFN

Degré de pureté : 98%

Masse moléculaire : 227.71

Ref: 54-PC1001134

Paroxetine EP Impurity G (Paroxetine USP Related Compound E) as Hydrochloride

Produit contrôlé

CAS : 1012886-75-7

Formule : C₁₂H₁₄FN·ClH

Couleur et forme : Neat

Masse moléculaire : 227.71

Ref: 86-MM1032.07

Paroxetine EP Impurity G

CAS : 1012886-75-7

Formule : C₁₂H₁₄FNHCl

Masse moléculaire : 191.2 : 36.46

Ref: ST-EA-CP-P3007

4-(4-Fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine Hydrochloride

Produit contrôlé

CAS : 1012886-75-7

Impurity Paroxetine EP Impurity G
Applications 4-(4-Fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine Hydrochloride (Paroxetine EP Impurity G) is the active metabolite of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (M325910), N-Methyl-4-phenylpyridinium (MPP+), selectively destroys the dopaminergic neurons and induces the symptoms of Parkinson's disease.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Gerlach, M., et al.: Eur. J. Pharmacol., 208, 273 (1991), Tipton, K., et al.: J. Neurochem., 61, 1191 (1993), Wimalasena, D., et al.: J. Biol. Chem., 279, 15298 (2004),

Formule : C₁₂H₁₄FN·ClH

Couleur et forme : Neat

Masse moléculaire : 227.71

Ref: TR-F595220

4-(4-Fluorophenyl)-1,2,3,6-tetrahydro-1-methylpyridine hydrochloride (1:1)

CAS : 1012886-75-7

4-(4-Fluorophenyl)-1,2,3,6-tetrahydro-1-methylpyridine hydrochloride (1:1) is a neuroleptic drug that has analgesic and antihistaminic effects. It is an alkylthio compound that inhibits serotonin release from the pre-synaptic neuron. 4-(4-Fluorophenyl)-1,2,3,6-tetrahydro-1-methylpyridine hydrochloride (1:1) also blocks the uptake of dopamine by nerve cells in the brain and prevents its conversion to norepinephrine. This medicine acts as an antagonist for both alpha and beta receptors because it binds to the benzene ring of these neurotransmitters. The alpha receptor antagonist properties of this drug are due to its ability to prevent norepinephrine from binding with alpha receptors on muscle cells. The beta receptor antagonist properties are due to its ability

Formule : C₁₂H₁₄FN•HCl

Degré de pureté : Min. 95%

Couleur et forme : Powder

Masse moléculaire : 227.71 g/mol

Ref: 3D-FF99746

USP Paroxetine Related Compound E Mixture

Produit contrôlé

CAS : 1012886-75-7, 110429-35-1

Applications USP Paroxetine Related Compound E Mixture is a reference standard composed of Paroxetine Hydrochloride (P205750) spiked with 4-(4-Fluorophenyl)-1,2,3,6-tetrahydro-1-methyl-pyridine Hydrochloride (F595220). Paroxetine Hydrochloride (P205750) is a selective serotonin reuptake inhibitor. Used as an antidepressant. 4-(4-Fluorophenyl)-1,2,3,6-tetrahydro-1-methyl-pyridine Hydrochloride (F595220) is the active metabolite of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (M325910), N-Methyl-4-phenylpyridinium (MPP+), selectively destroys the dopaminergic neurons and induces the symptoms of Parkinson's disease.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Lassen, J.B.: Eur. J. Pharmacol., 47, 351 (1978), Lund, J., et al.: Acta Pharmacol. Toxicol., 51, 351, (1982); Gerlach, M., et al.: Eur. J. Pharmacol., 208, 273 (1991), Tipton, K., et al.: J. Neurochem., 61, 1191 (1993), Wimalasena, D., et al.: J. Biol. Chem., 279, 15298 (2004),

Formule : C₁₉H₂₀FNO₃·C₁₂H₁₄FN·HCl

Couleur et forme : Neat

Masse moléculaire : 557.07

Ref: TR-P205790